Malignant Melanoma
Conditions
Keywords
CP-4055, Elacyt, Cancer, Metastatic, Malignant melanoma, Combination treatment, Sorafenib, Nexavar
Brief summary
Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until complete response or disease worsening/progressing.
Detailed description
This is a multicentre clinical study conducted in the USA and in Europe. It is an open label study designed to investigate objective tumor response, the time to progression (TTP) and the duration of tumor response in patients with metastatic malignant melanoma when treated with CP-4055 in combination with sorafenib (Nexavar®). The safety and tolerability of the treatment will also be assessed.
Interventions
DRUGCP-4055
CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
Sponsors
Clavis Pharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with histological or cytological confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have or have not undergone prior chemotherapy for the treatment of melanoma 2. Measurable disease according to Response Criteria In Solid Tumors (RECIST) 3. Performance Status 0 - 1 according to ECOG (Eastern Cooperative Oncology Group) Performance Status 4. Age 18 years or more 5. Life expectancy \> 3 months 6. Signed informed consent 7. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this study 8. Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last CP-4055 dose 9. Adequate haematological and biological functions
Exclusion criteria
1. Known brain metastases 2. Diagnosis of ocular malignant melanoma 3. Radiotherapy to more than 30 % of bone marrow 4. Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study 5. Requirement of concomitant treatment with a non-permitted medication: * Alternative drugs * High doses of vitamins 6. History of allergic reactions to ara-C or egg 7. History of allergic reactions attributed to compounds of similar chemical or biological composition to sorafenib 8. Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection) 9. Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance 10. Pregnancy, breastfeeding or absence of adequate contraception for both male and female fertile patients 11. Known positive status for HIV and/or hepatitis B or C 12. Drug and/or alcohol abuse 13. Any reason why, in the investigator's opinion, the patient should not participate 14. Prior treatment with CP-4055 and/or sorafenib 15. Significant history of cardiac disease, including any of the following: * Uncontrolled hypertension * Unstable angina pectoris * Congestive heart failure * Myocardial infarction within the past 6 months * Unstable ventricular arrhythmia * Other cardiac arrhythmia 16. Condition that impairs ability to swallow pills 17. Tendency of bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Objective tumour response | October 2008 |
Secondary
| Measure | Time frame |
|---|---|
| • Time to progression | October 2008 |
| • Duration of tumour response | October 2008 |
| • Safety and tolerability of treatment | October 2008 |
Countries
Norway, Sweden, United States
Outcome results
None listed